Results 131 to 140 of about 54,012 (256)

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

The Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo, Akimichi Morita, Yayoi Tada, Shinichi Imafuku, April W. Armstrong, Andrew Blauvelt, John Vaile, Zoran Popmihajlov, Janice Li, Rajesh Sawant, Katsuyoshi Habiro, Katsuki Tsuritani, Mamitaro Ohtsuki   +12 more
wiley   +1 more source

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions. [PDF]

Drug Des Devel Ther
Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR.   +6 more
europepmc   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Comprehensive Morphological and Immunohistochemical Evaluation of Gastrointestinal Stromal Tumors: Insights From a Tertiary Care Center. [PDF]

Cureus
Pol V, Patil M, Dugad V, Pol JN, Bhosale A, Agarwal A, Deshpande P.   +6 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

GALNT7 promotes the malignant progression of gastrointestinal stromal tumors by regulating KIT O-GalNAc glycosylation. [PDF]

Precis Clin Med
Liu J, Wu S, Wang Y, Zhang G, Li J, Wang Z, Yin Y, Liu H, Peng S, Fu Y.   +9 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

Quality of Life and Experiences of Patients with Gastrointestinal Stromal Tumors (GIST) on Imatinib Treatment. [PDF]

J Gastrointest Cancer
Westerdijk K, Steeghs N, van der Graaf WTA, Groen JS, van Erp NP, Hermens RPMG, Desar IME.   +6 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source